BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
An Uncontrolled Phase II Multi-Center Trial Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Advanced Renal Cell Cancer
Sponsor: Theradex
A PHASE2 clinical study on Kidney Cancer, this trial is ongoing. The trial is conducted by Theradex and has accumulated 6 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Dec 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Theradex
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States, Billings, United States, Calgary, Canada, Edmonton, Canada, Greenbelt, United States, La Jolla, United States, Milwaukee, United States, Muncie, United States, New Brunswick, United States, New Orleans, United States and 3 more location s